Important Information for Investors of Cassava Sciences, Inc. (SAVA)
New York, NY – Rosen Law Firm, a leading global investor rights law firm, alerts investors of Cassava Sciences, Inc. (SAVA) regarding a potential securities class action lawsuit. The alleged securities fraud class action lawsuit is pending in the United States District Court for the Eastern District of Texas and seeks to recover damages for Cassava Sciences investors who purchased securities of the company between February 7, 2024, and November 24, 2024, both dates inclusive (the “Class Period”).
Background on Cassava Sciences, Inc.
Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapies for neurodegenerative diseases, including multiple sclerosis (MS) and Alzheimer’s disease. Its lead product candidate, PF-06648251 (Pimobidan), is an oral selective pimobisylphosphatase inhibitor in development for the treatment of MS and other neurodegenerative diseases.
Allegations of Securities Fraud
The complaint alleges that defendants made materially false and misleading statements and failed to disclose material information during the Class Period. Specifically, the complaint alleges that: (1) Cassava Sciences’ PF-06648251 (Pimobidan) did not demonstrate the clinical benefit suggested by the company; and (2) as a result, the company’s public statements were materially false and misleading at all relevant times.
Lead Plaintiff Deadline
If you purchased Cassava Sciences securities during the Class Period, you may be entitled to compensation without intervention of a lawyer. So far, the lawsuit has been filed on behalf of the lead plaintiff. If you wish to act as lead plaintiff, you must apply to the Court by February 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Impact on Individual Investors
If you purchased Cassava Sciences securities during the Class Period and believe that the company misrepresented the clinical benefit of its lead product candidate, PF-06648251 (Pimobidan), you may be able to recover your losses as part of a securities class action lawsuit. The lead plaintiff deadline is February 10, 2025. To learn more about the lawsuit and your potential recovery, contact the Rosen Law Firm at 212-614-5450 or [email protected], or visit the firm’s website at
Impact on the World
The alleged securities fraud at Cassava Sciences has significant implications for the biotechnology industry and investors. The case highlights the importance of accurate and transparent reporting by publicly traded companies, particularly in the field of clinical-stage research and development. The outcome of this lawsuit could set a precedent for future securities fraud cases involving biotechnology companies and their investors.
Conclusion
Rosen Law Firm encourages investors who purchased Cassava Sciences securities during the Class Period to contact the firm for more information about the securities class action lawsuit. The firm represents investors worldwide, and it has a proven track record of recovering significant damages for investors.
- Investors who purchased Cassava Sciences securities during the Class Period may be entitled to compensation as part of a securities class action lawsuit.
- The lead plaintiff deadline is February 10, 2025.
- Contact Rosen Law Firm at 212-614-5450 or [email protected] for more information.
- The outcome of this lawsuit could have significant implications for the biotechnology industry and investors.
About Rosen Law Firm: Rosen Law Firm represents investors worldwide, focusing on securities class actions and other complex litigation. The firm is dedicated to protecting investors from fraud and other deceitful business practices.
